Mirtazapin-Ct Abz (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin-Ct Abz, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapin-Ct Abz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine belongs to the NaSSA class and is used to manage depressive disorders. - Major depressive disorder: alleviates depressive symptoms and improves mood in adult patients. - Depressive episodes associated with major depressive disorder: reduces severity and frequency of episodes. - Treatment‑resistant depression (as adjunct): may enhance response when other antidepressants are insufficient.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness: feeling unusually sleepy, especially at treatment initiation. - Increased appetite and weight gain: notable rise in hunger and body weight. - Dry mouth: reduced salivation leading to discomfort. - Constipation: slowed gastrointestinal motility. - Dizziness: light‑headed sensation, particularly when standing quickly.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia: marked reduction in white blood cells. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Suicidal thoughts or behavior: emergence of self‑harm ideation. - Hepatic dysfunction: abnormal liver enzyme elevations. - Severe hypotension: marked drop in blood pressure, especially when combined with other depressants. - Seizures: rare occurrence of convulsive episodes.

When prescribing or dispensing mirtazapine, clinicians should consider several safety measures. - Monitor weight: track changes due to appetite stimulation. - Assess for suicidal ideation: especially during early treatment phases. - Use caution in hepatic impairment: adjust therapy if liver function is compromised. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Review concomitant CNS depressants: evaluate additive sedation risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis or serotonin syndrome. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Other CNS depressants (benzodiazepines, alcohol): additive sedation and respiratory depression. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: potential for serotonin syndrome. - CYP3A4 inhibitors (ketoconazole, erythromycin): may modestly raise mirtazapine concentrations.